Link to this page
The Drug-Drug Interactions Ontology
| Preferred Name | prasugrel | |
| Synonyms |
C20H20FNO3S 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4H,5H,6H,7H-thieno[3,2-c]pyridin-2-yl acetate |
|
| ID |
http://purl.obolibrary.org/obo/dinto_DB06209 |
|
| AHFScode |
20:12.18
|
|
| ATCCode |
B01AC22
|
|
| binds |
http://purl.obolibrary.org/obo/dinto_0217 http://purl.obolibrary.org/obo/dinto_2806 http://purl.obolibrary.org/obo/dinto_2058 http://purl.obolibrary.org/obo/dinto_0291 http://purl.obolibrary.org/obo/dinto_0901 |
|
| blocks | ||
| CASRN |
150322-43-3
|
|
| DBBrand |
efient effient prasita
|
|
| DBSalt |
prasugrel hydrochloride
|
|
| DBSynonym |
cs-747 ly-640315
|
|
| Definition |
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
|
|
| has effect |
http://purl.obolibrary.org/obo/OAE_0000388 http://purl.obolibrary.org/obo/OAE_0000377 http://purl.obolibrary.org/obo/OAE_0000218 http://purl.obolibrary.org/obo/OAE_0000659 http://purl.obolibrary.org/obo/OAE_0000406 http://purl.obolibrary.org/obo/OAE_0000650 http://purl.obolibrary.org/obo/OAE_0001013 http://purl.obolibrary.org/obo/OAE_0001448 http://purl.obolibrary.org/obo/OAE_0000600 http://purl.obolibrary.org/obo/OAE_0000310 http://purl.obolibrary.org/obo/OAE_0000476 http://purl.obolibrary.org/obo/OAE_0000403 http://purl.obolibrary.org/obo/OAE_0001463 http://purl.obolibrary.org/obo/OAE_0000551 http://purl.obolibrary.org/obo/OAE_0001014 http://purl.obolibrary.org/obo/OAE_0001374 http://purl.obolibrary.org/obo/OAE_0000584 http://purl.obolibrary.org/obo/OAE_0001129 http://purl.obolibrary.org/obo/OAE_0001281 http://purl.obolibrary.org/obo/OAE_0000414 http://purl.obolibrary.org/obo/OAE_0000034 http://purl.obolibrary.org/obo/OAE_0000508 http://purl.obolibrary.org/obo/OAE_0000022 http://purl.obolibrary.org/obo/OAE_0001205 http://purl.obolibrary.org/obo/OAE_0000487 http://purl.obolibrary.org/obo/OAE_0000362 |
|
| has pharmacological target | ||
| InChI |
InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
|
|
| InChIKey |
InChIKey=DTGLZDAWLRGWQN-UHFFFAOYSA-N
|
|
| is metabolised by |
http://purl.obolibrary.org/obo/dinto_2058 http://purl.obolibrary.org/obo/dinto_0291 http://purl.obolibrary.org/obo/dinto_0901 |
|
| is substrate of |
http://purl.obolibrary.org/obo/dinto_0217 http://purl.obolibrary.org/obo/dinto_2058 http://purl.obolibrary.org/obo/dinto_0291 http://purl.obolibrary.org/obo/dinto_0901 |
|
| label |
prasugrel
|
|
| may interact with |
http://purl.obolibrary.org/obo/CHEBI_5855 http://purl.obolibrary.org/obo/CHEBI_6375 http://purl.obolibrary.org/obo/CHEBI_10033 http://purl.obolibrary.org/obo/dinto_DB00503 |
|
| modulates | ||
| prefixIRI |
obo2:dinto_DB06209
|
|
| prefLabel |
prasugrel
|
|
| SMILES |
CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1
|
|
| Synonym |
C20H20FNO3S 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4H,5H,6H,7H-thieno[3,2-c]pyridin-2-yl acetate
|
|
| xref |
PDRhealth:http://www.pdrhealth.com/drugs/effient RxList:http://www.rxlist.com/effient-drug.htm PubChem Compound:6918456 PharmGKB:PA154410481 PubChem Substance:99443238 National Drug Code Directory:54868-6238-0 ChemSpider:5293653 Wikipedia:http://en.wikipedia.org/wiki/Prasugrel Drugs.com:http://www.drugs.com/cdi/prasugrel.html
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |